- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01509716
Assessing Perceived Versus Actual Knowledge and Quality of Life in Pre-Dialysis Chronic Kidney Disease (CKD) Patients
Assessing Perceived Versus Actual Knowledge and Quality of Life in Pre-Dialysis CKD Patients
Aims: The investigators' primary objective is to assess both perceived and actual disease knowledge in local pre-dialysis Chronic Kidney Disease (CKD) patients. The investigators hypothesize that actual disease knowledge is poorer than perceived. As the secondary objectives, the investigators will also assess the HRQoL and examine the association between level of knowledge and HRQoL in pre-dialysis CKD patients. The investigators hypothesize that HRQoL of pre-dialysis CKD patients is poorer than that of the general population while pre-dialysis CKD patients with greater disease knowledge have a better HRQoL than those with poorer knowledge.
Methodology: A survey was developed to assess both perceived and actual knowledge on five aspects - general knowledge, nephrotoxic medications, diet restrictions, symptoms of CKD and its complications and renal replacement therapy (RRT) options. For the assessment of HRQoL, the following questionnaires will be used - Kidney Disease Quality of Life-Short Form (KDQOL-SF) version 1.3, EuroQoL 5 Dimensions (EQ-5D), Family Functioning Measure (FFM), and Oslo-3 Social Support Scale (OSS-3). All study questionnaires will be provided in 3 main languages - English, Chinese and Malay. A standardized data collection form was developed to retrospectively collect demographic and clinical information from the patients' electronic medical records and patient charts. Descriptive statistics will be used to report all results.
Study Overview
Status
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Priscilla P How, Pharm.D.
- Phone Number: (65) 6516 4906
- Email: priscillahow@nus.edu.sg
Study Locations
-
-
-
Singapore, Singapore
- Recruiting
- National University Hospital
-
Contact:
- Priscilla P How, Pharm.D.
- Phone Number: (65) 6516 4906
- Email: priscillahow@nus.edu.sg
-
Principal Investigator:
- Priscilla P How, Pharm.D.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients at least 21 years of age,
- able to read English, Chinese or Malay,
- have stage 3 to 5 CKD as identified from their medical records, but are not receiving dialysis.
Exclusion Criteria:
- patients who do not consent,
- have already been started on dialysis,
- are cognitively impaired as assessed by the recruiter or unable to fill up questionnaires on their own.
Study Plan
How is the study designed?
Design Details
- Time Perspectives: Cross-Sectional
Collaborators and Investigators
Sponsor
Study record dates
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DSRB Domain E/2011/02008
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Disease Stage 5
-
Heinrich-Heine University, DuesseldorfRecruitingVaccine Response Impaired | Chronic Kidney Disease Stage 5 on Dialysis | Chronic Kidney Disease Stage 5 With TransplantGermany
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
University of MichiganTheravance BiopharmaCompletedEnd-Stage Renal Disease | Stage 5 Chronic Kidney DiseaseUnited States
-
University of ManitobaRecruitingCKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients (VIEWER)End Stage Renal Disease | Chronic Kidney Disease Stage 5Canada
-
Zydus Lifesciences LimitedCompletedAnemia | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4India
-
ArdelyxAstraZenecaCompletedEnd Stage Renal Disease | ESRD | Chronic Kidney Disease Stage 5United States
-
liberDi Ltd.RecruitingChronic Kidney Disease Stage 5Israel
-
ShireCompletedChronic Kidney Disease, Stage 5United States, Germany, Puerto Rico, United Kingdom
-
National University of SingaporeUnknownStage 5 Chronic Kidney DiseaseSingapore
-
Savient PharmaceuticalsCompletedChronic Kidney Disease Stage 5United States